AugmAb

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameAugmAb
Drug Alias NamemAb therapy (Compliment)mAb therapy (PAI Life)mAb therapy (Compliment/PAI Life)mAb therapy (Compliment/PAI Life)BRM-132
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionMembrane cofactor protein inhibitorsMembrane cofactor protein modulators
TargetsMembrane cofactor protein
Therapy Area/IndicationsLymphoma, Non-HodgkinNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwan
CombinationsYes
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCompliment Corp
China Registration ClassN/A

Develop Information

Active CompaniesCompliment CorpPAI Life Sciences IncBrim Biotechnology Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-Hodgkin
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A